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High dose selenium acts as a cytotoxic agent, with potential applications in cancer treatment. However, clinical trials have failed to show
any chemotherapeutic value of selenium at safe and tolerated doses (b90 μg/day). To enable the successful exploitation of selenium for
cancer treatment, we evaluated inorganic selenium nanoparticles (SeNP), and found them effective in inhibiting ovarian cancer cell growth.
In both SKOV-3 and OVCAR-3 ovarian cancer cell types SeNP treatment resulted in significant cytotoxicity. The two cell types displayed
contrasting nanomechanical responses to SeNPs, with decreased surface roughness and membrane stiffness, characteristics of OVCAR-3 cell
death. In SKOV-3, cell membrane surface roughness and stiffness increased, both properties associated with decreased metastatic potential.
The beneficial effects of SeNPs on ovarian cancer cell death appear cell type dependent, and due to their low in vivo toxicity offer an exciting
opportunity for future cancer treatment.
© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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primarily through the diet as selenium containing amino acids,1
however it has a narrow safe range of exposure and becomes
toxic at levels above the recommended dietary intake (30-90 μg/
day). Selenoproteins are implicit in human health due to their
antioxidant activity and are associated, for example, with anti-
inflammatory, and antiviral properties.2 Selenocysteine (SeCys)
is present in Se containing proteins, predominantly glutathione
peroxidase (GPX) in the liver, and is involved in reactive oxygen
species (ROS) scavenging through its redox function.3 GPX
reduces lipid hydroperoxides in alcohols and reduces free
hydrogen peroxide to water.
Observational studies revealed that Se can inhibit cancer cell
growth. This effect occurs through increasing ROS-mediated
necrosis in prostate cancer,4 autophagy in colorectal cancer,5 and
apoptosis in skin, breast, and liver cancer.6 However, a meta-The authors declare no conflict of interest.
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1549-9634/© 2020 The Author(s). Published by Elsevier Inc. This is an open acanalysis of randomized controlled trials, N25,000 patients, failed
to show any significant effect of Se dietary supplementation in
reducing the incidence of colorectal, skin, lung, bladder or
prostate cancer.7 High supplementation levels induced toxicity
limiting the utility of Se containing compounds as potential
chemotherapeutic agents.8 To overcome the toxicity associated
with soluble Se, Se-nanoparticles (SeNPs) have been synthesized
and evaluated for their anticancer properties. Both free-SeNPs9
and encapsulated-SeNPs10 are effective in reducing cancer cell
proliferation in vitro. Furthermore, SeNPs appear to be effective
and well tolerated in vivo 11, enabling Se to be used effectively at
doses that would be toxic if administered as soluble Se.
Ovarian cancer is the seventh most common cancer in women
with five-year survival rates of less than 45%,8 and only 20% of
cases are detected at early stages of the disease.12 The ovarian
micro-environment cancer is highly inflammatory, and the use ofcal School.
cess article under the CC BY-NC-ND license (http://creativecommons.org/
Figure 1. SeNP characterization and internalization. Representative TEM images of the SeNP-BSA (A) and SeNP-chitosan (B). Images have been taken with
x23000 magnification. Treatment for 48 h with sublethal doses of selenite, SeNP-BSA and SeNP-chitosan resulted in significant alteration (C) in SKOV-3 (left)
or OVCAR-3 (right) cells expression of GPX1. In untreated SKOV-3 relative GPX1 expression levels were respectively 0.08 +/− 0.01 for control, 0.25 +/− 0.03
for selenite, 0.26 +/− 0.06 SeNP-BSA, 0.19 +/− 0.03 for SeNP-Chitosan. Same pattern have been observed in OVCAR with 0.13 +/− 0.01 for control, 0.28 +/−
0.03 for Selenite, 0.34 +/− 0.03 SeNP-BSA, 0.26 +/− 0.05 SeNP-Chitosan. All measurement representative of a minimum 3 biological repeats.
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risk of cancer development13 , possible due to the form of
selenite used in supplements forming endogenous SeNPs that
inhibit glycolysis, causing mitochondrial dysfunction, autophagy
and cytoskeletal depolymerisation.14
Tumor metastasis in advanced ovarian disease is the leading
cause of death and is an inherently mechanical process where
these properties are known to be altered.16,17 The acquisition of
invasiveness by tumor initiating cells is accompanied by the loss
of the epithelial features and the gain of a mesenchymal
phenotype, termed epithelial to mesenchymal transition
(EMT).15 Chemotherapeutic drugs have been shown to modify
such cellular biomechanical features, through architectural
changes to the cell cytoskeleton.18 Similarly cellular cytoskeletal
components such as actin microfilaments, intermediate fila-
ments, and microtubule polymer networks play determinant roles
in cellular mechanical properties, locomotion, while regulating
cellular integrity during differentiation.18 Modifications to those
networks influence cytoadherence, migration, invasion and
tumor metastasis.19,20
Here, we assessed the anticancer activity of protein (BSA)
and carbohydrate (chitosan) surface coated SeNPs in two distinct
high grade serous ovarian cancer cell lines, OVCAR-3 and
SKOV-3. Both SeNPs were significantly more cytotoxic than
soluble Se in OVCAR-3 cells at high doses (N40μg/mL), but
similar to soluble Se with SKOV-3 cells, which were more
sensitive to Se treatment than OVCAR-3 cells, highlighting the
differences between cell types. Further analysis revealed SKOV-
3 cells exhibited stable EMTmarkers and decreased motility, andinterestingly, an increase cell surface roughness and cellular
stiffness. In contrast OVCAR-3 cells displayed a decrease in
cellular stiffness indicative of altered cytoskeletal dynamics that,
alongside decreased vimentin expression levels and autophagy,
can be interpreted as sensitization toward apoptosis.5 ,6 ,21 It
appears that reduction in cell viability following SeNP exposure
occurs through different mechanisms that result in contrasting
perturbations in cellular mechanics in serous ovarian cancer
subtypes. SeNPs may therefore offer the potential for pan-cancer
treatments, not least in ovarian cancer, that is a complex and
multifaceted disease with a very poor prognostic outcome.Methods
Cell culture
The OVCAR-3 (ATCC, Rockville, MD, USA) ovarian
cancer cells were cultured in RPMI-1640 (Sigma-Aldrich,
Gillingham, UK) supplemented with 20% bovine serum albumin
(BSA, Sigma-Aldrich, UK), 5 μg/mL insulin (Sigma-Aldrich,
Gillingham, UK), and 1% penicillin-streptomycin (v/v) solution
(Sigma-Aldrich, UK). The SKOV-3 (ATCC, Rockville, MD,
US) ovarian cancer cells were cultured in McCoy’s 5A (Sigma-
Aldrich, Gillingham, UK) supplemented with 10% bovine serum
albumin (BSA, Sigma-Aldrich, UK), and 1% penicillin-
streptomycin (v/v) (Sigma-Aldrich, Gillingham, UK). Cells
were maintained at 37°C and 5% CO2 and routinely passaged
using 0.25% trypsin - 0.1% EDTA (v/v).
Figure 2. SeNP cytotoxicity. Ovarian cancer cells SKOV-3 (top) and OVCAR-3 (bottom) were grown in the presence of Selenite, BSA coated selenium
nanoparticles or chitosan coated selenium nanoparticles over 48 h and monitored for cellular cytotoxicity. Both cell lines were treated for 48 h with an increasing
range of concentration from 0 to 80 μg/mL. Cytotoxicity was evaluated by RTGlo and mean (+/−SD) luminescence values shown) from four independent
experiments. SKOV-3 and OVCAR-3 viability are presented in comparison with control in supplementary figure 1.
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SeNPs were purchased from NANOCS (New York, USA)
with two different coatings, BSA and chitosan. Manufacturer
specifications stated 25 – 50 nm of diameter for both
nanoparticles. Size shape and charge analysis was conducted
by Dynamic Light Scattering and Zeta Potential measurement
using a ZetaSizer Nano (Malvern Instruments, Malvern, UK)
with a 173° scattering angle using SeNPs at 1μg/mL in water
(reflexive index of 1.33) at 25°C.
Cell growth and Se treatment
Both SKOV-3 and OVCAR-3 cells were cultured in growth
medium until 80% confluency, trypsinized per regular passage
and seeded to sterile petri dishes (Corning, UK) at 37° C and 5%
CO2. After 48 h incubation culture medium was removed and 2
mL of fresh medium containing the expected concentration of
aqueous Se (selenite Se4+) or SeNPs added for a further 48 h
prior to analysis, with a minimum of three biological repeats.
Cell viability assay
Ovarian cancer cell viability in the presence and absence of
Se treatments was determined using the Real-Time Glo assay
(RTGlo, PROMEGA, Southampton, UK). 1 × 103 ovarian
cancer cells/well were plated within 96-well white plates
(Corning, UK). After 24 h of growth, culture media was
aspirated and 100 μL of fresh medium containing aqueous Se
(selenite Se4+) or SeNPs (BSA or chitosan) were added. An
increasing dose range (0.06 μg/mL to 40 μg/mL) was applied by
dilution in appropriate medium for 48 h. The RTGlo with RPMI-
1640 medium was added 1:1 with treatment medium. A BMGLabtech Fluostar Omega was used to measure luminescence
every 24 h and presented as absolute values. IC20/IC50 doses
were determined as the concentration of treatment that reduced
by 20%/50% the luminescence signal compared to untreated
control. The IC20/IC50 values shown (average ± standard
deviation) are from a minimum of four independent experiments
performed with 6 technical repeats.
Migration assay
2 × 105 SKOV-3 cells/per well were seeded in 12 well plates
and cultured in complete culture medium until the cells reached
confluence. A scratch was then introduced to the monolayers,
using a sterile (20 μL pipette) tip. The media was then aspirated
and a fresh, fetal bovine serum (FBS, Gibco, UK) free medium
containing IC20 selenium treatment was added to each well and
cultured for 48 h. The scratch was imaged at 0, 24, 48 h using a
Primo Vert inverted light microscope (Zeiss, Cambridge, UK).
Average scratch width measurements were measured at three
random areas, in three wells for each condition, as previously
reported.22 The migration rate was calculated according to the
following equation: cell motilities (%) = [1 − (distance of
scratched area at 24 h/distance of scratched area at 0 h)]
×100%.
Protein blotting
Total cellular protein was extracted using TRIzol™ reagent
(Sigma, Gillingham, UK) and quantified using the DC™ Protein
Assay (BioRad, Deeside, UK). Protein from each sample
was mixed with Laemmli sample buffer containing β-
mercaptoethanol (5%) and boiled at 95°C for 5 min. Equal
Figure 3. Effect of SeNPs on EMT phenotype. Scratch/wound healing assay (A) results showed that selenite, SeNP-chitosan and SeNP-BSA treatments at IC20
significantly decreased migration of SKOV-3 cells during 48 h. SeNP-BSA treatment decreases the recovery rate by 25% (+/−4.8%), SeNP-chitosan treatment
by 16.5% (+/−3.8%) and selenite treatment by 18.6 (+/−8.2%) in comparison with control (P b 0.05). It was not possible to complete the migration assay with
OVCAR-3 cells as they do not survive when depleted with FBS. Treatment for 48 h with IC20 selenite, SeNP-BSA and SeNP-chitosan resulted in no significant
alteration in SKOV-3 or OVCAR-3 cells profiling of EMT markers (E-cadherin, N-cadherin, Vimentin) (C, D). In untreated SKOV-3 (C) relative vimentin
expression levels were similar between conditions with respectively 0.9 (+/−0.2) for control, 1.01 (+/−0.1) for selenite, 1.14 (+/−0.02) for BSA SeNP, 0.87 (+/
−0.11) for chitosan SeNP. Relative expression of E-cadherin was low (0.01 to 0.02). N-cadherin expression was similar between conditions with respectively 0.8
(+/−0.08) for control, 0.67 (+/−0.01) for selenite, 0.9 (+/−0.01) for BSA SeNP, 0.76 (+/−0.05) for chitosan SeNP. In untreated OVCAR-3 (D) relative vimentin
expression levels were 0.45 (+/−0.08) while it was decreased in treated cells with 0.31 (+/−0.1) with selenite, 0.20(+/−0.03) for BSA SeNP and 0.18(+/−0.06) for
chitosan SeNP. Relative expression of N-cadherin was very low (0.02 to 0.05). E-cadherin expressions were the same between the different conditions with 0.50
(+/−0.05) for control, 0.45 (+/−0.2) for selenite, 0.47 (+/−0.05) for SeNP-BSA and 0.5 (+/−0.002) for chitosan SeNP. Examples of western blots have been
displayed in (B).
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20% gels) and subsequently transferred onto a PVDFmembrane
(Biorad, Deeside, UK). The membranes were blocked for 1 h in
5% BSA prepared in 0.1% Tris-buffered saline-Tween20®
(TBS-T). Blots were then incubated with the corresponding
primary antibody (E-cadherin: mouse monoclonal (Abcam
ab1416, Cambridge, UK), vimentin: mouse monoclonal (Santa
Cruz sc-6260, Wembley, UK), N-cadherin: rabbit polyclonal
(Abcam ab18203, Cambridge, Wembley, UK) or GAPDH:
mouse monoclonal (Santa Cruz sc-47724, Wembley, UK)) at a
concentration of 200 μg/mL overnight at 4°C. Blots were then
washed 3 times with TBS-T and incubated at room temperature
for 1 h with the appropriate secondary antibody (goat anti-
mouse Abcam ab150113 or goat anti-rabbit Abcam ab6721
HRP secondary, Cambridge, UK) at a concentration of 400 μg/
mL. For signal detection, membranes were processed using the
Clarity™ Western ECL Substrate kit (BioRad, Deeside, UK)
according to the manufacturer's recommendations and visual-
ized using a ChemiDoc XRS system (BioRad, Deeside, UK).
Analysis of the intensity of the bands was done using Image
Lab (BioRad, Deeside, UK) software tracing fixed size-limitedrectangle around the bands of interest and reporting the
Adjusted Volume (Intensity corrected by the background
noise). Protein expression was normalized GAPDH and
relative expression expressed as the mean fold induction ±
standard deviation.
qRT-PCR
Following RNA extraction and quantification, qPCR
was carried out in accordance with the manufacturers' recom-
mendations, using the RETROscript® kit two-step
method (Invitrogen Ltd., UK). Following cDNA synthesis
from 100 ng of RNA, each sample was analyzed by qPCR in
triplicate using iQ SYBR Green supermix (BioRad, Deeside,
UK) and gene specific primers (Sigma-Aldrich, Gillingham, UK)
to evaluate different gene expression GAPDH (GAPDH
Fo rwa r d : GTCCACTGGCGTCTTCAC, Reve r s e :
CTTGAGGCTGTTGTCATACTTC) and GPX1 (GPX1 For-
ward: GTGCTCGGCTTCCCGTGCAAC, Reverse: CTCGAA-
GAGCATGAAGTTGGGC). Serial dilutions of cDNA were
used to plot a calibration curve, and gene expression quantified
Figure 4. Effect of SeNP on SKOV-3 morphology and topography. SKOV-3 cells were treated with Se-NPs for 48 h and compared to selenite (IC20) and an
untreated control. High resolution AFM imaging was performed and subsequent image analysis. No morphological and/or topographical cell changes were
detected with stable morphological features observed in the Control (A), IC20 Selenite (B), IC20 BSA coated SeNP (C), IC20 chitosan coated SeNP (D) using
bright field, AFM height and PeakForce error signal respectively. The shown image is representative of the morphology of SKOV-3, from imaging 15 cells from
3 biological repeats.
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normalized to values obtained for the reference gene (GAPDH)
and relative expression expressed as the mean fold induction ±
standard deviation. Statistical differences between the treat-
ment groups and the control were determined by analysis of
variance (ANOVA) (where P b 0.05 was considered
significant).
AFM analysis
Young modulus, indentation and adhesion
Force-indentation curves were obtained using a Nanowizard
II AFM (JPK, Berlin, Germany) mounted on a ZEISS 510
confocal microscope (Zeiss, Cambridge, UK) as described in23.
During AFM, cells were kept alive in serum free, pH indicator
free culture media at 37°C in a petri dish using a standard stage
heater and analyzed for a maximum of 3 h. The inverted optical
microscope was used to position the tip on the cell and force
volume conducted using borosilicate colloidal (Novascan, UK)
cantilevers, with a nominal spring constant of 0.35 N/m with a
radius of 2.5 μm. Prior to measurements, deflection sensitivity
and spring constant were experimentally determined, the latterusing the subroutine of the JPK software. Three individual force
curves (ramp size of 6 μm) were taken on a total of 25 cells,
across 3 independent biological experiments, using a maximum
force indentation of 6 nN was used. JPK Data Processing
program was used to process the acquired force curves. For each
force curve the baseline was corrected to 0 and the approach
curve in the contact regime of each force curve was fitted using
the classical Hertz model according to Eq. 1. In both cases, the
fitting module in the JPK software was used and only curves with
a goodness of fit between 0.85 and 1 were considered for
statistical analysis.
RRMS ¼
ffiffiffiffiffiffiffiffiffiffiffiP
Z2i
N
s
ð1Þ
In this equation, F is the force applied by the cantilever tip to
the cell, E is the Young's modulus (fit parameter), υ is the
Poisson’s ratio (0.5), R the radius of the indenter, δ is the
indentation depth and α is the half-angle of the indenter (18° for
the used sharp probes).
Figure 5. Effect of SeNP on OVCAR-3 morphology and topography. OVCAR-3 cells were treated with Se-NPs for 48 h and compared to selenite (IC20) and
an untreated control. High resolution AFM imaging was performed and subsequent image analysis. No morphological and/or topographical cell changes were
detected with stable morphological features observed in the Control (A), IC20 selenite (B), IC20 BSA coated SeNP (C), IC20 chitosan coated SeNP (D) using
bright field, AFM height and PeakForce error signal respectively. The shown image is representative of the morphology of OVCAR-3, from imaging 15 cells
from 3 biological repeats.
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In order to resolve the membrane architecture, cells were
fixed for imaging according to the protocols outlined in Francis
et al. 24 Briefly cells were washed 2 times with PBS then fixed
for 30 min in 4% PFA (Merck, UK) diluted in PBS at RT. PFA
was subsequently removed and replaced by phosphate buffered
saline (PBS), at RT. SKOV-3 and OVCAR-3 cell morphology
and topography were analyzed using a BioScope Catalyst
(Bruker Instruments, USA) mounted on a Nikon Eclipse Ti-S
inverted optical microscope (Nikon Instruments, Netherlands).
The inverted optical microscope was used to carefully position
the tip on the desired cell and tapping mode imaging undertaken
using MLCT-E silicon nitride cantilevers (Bruker-Nano, UK).
Offline processing for AFM height data consisted of first-order
flattening and plane fitting. The membrane roughness was
measured using the subroutine in the Nanoscope Analysis
software v1.50, on areas of 25 μm2 each on five cells for control
and treated, from a minimum of 3 biological repeats. Membrane
roughness was calculated using Eq. 2,
RRMS ¼
ffiffiffiffiffiffiffiffiffiffiffiP
Z2i
N
s
ð2Þwhere N is the number of height points in the analyzed area
and Zi is the vertical distance of data point i from the mean image
data plane. Sixteen roughness measurements were calculated per
image, with 1 μm2 areas of measurement.
Statistical analysis
All data presented are calculated from a minimum of three
biological repeats, with technical repeats included per sample, as
denoted. Data normality was analyzed using the Kolmogorov
Smirnov test, with normally distributed data analyzed with the
one-way and two-way analysis of variance (ANOVA) or the
Mann–Whitney pairwise test for non-parametric data. In all cases
in which ANOVA was significant, multiple comparison methods
were used. Differences were considered significant for P ≤ 0.05
(*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001). All data were analyzed
in MiniTab 14.Results
Physicochemical and biological characterization of SeNPs
Based on previous observations showing Se has anti-proliferative
effects on ovarian cancer cells,14,25,26 and the good tolerability of
Figure 6. Effect of SeNP on SKOV-3 and OVCAR-3 surface roughness.Cell roughness (SKOV-3 (B) and OVCAR-3 (C)) was calculated on height cells with
25μm2 areas measurement and 1μm2 analysis squares in all groups. Images of example areas are displayed in A. SKOV-3 control cell surface roughness (RRMS=
33.08 +/− 1.56 nm) was similar with selenite treated cells (RRMS=26.41 +/− 1.15 nm) and significantly lower than observed in SeNP treated cells (RRMS=37.31
+/− 1.58 nm for BSA and RRMS=42.89 +/− 2.37 nm for Chitosan). OVCAR-3 control cell surface roughness (RRMS =39.39 +/− 2.48 nm) was significantly higher
than that observed in treated cells (RRMS=28.41 +/− 1.82 nm in selenite treated cells, RRMS=27.92 +/− 1.75 nm in BSA coated SeNP treated cells and RRMS=
30.05 +/− 1.11 nm in chitosan coated SeNP).
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cytotoxicity of BSA and chitosan coated SeNP on SKOV-3 and
OVCAR-3 cells. Characterization of SeNPs (see supplementary
figure 2) aggregation and charge demonstrated SeNP-BSA had a
negative charge (-51.2 ± 15.8 mV) and an average size of 108 ± 30
nm and PDI of 0.123 ± 0.002 which was considered monodisperse,
and the 30-100 nm size range confirmed by transmission
electron microscopy (TEM) (Figure 1, A and B). SeNP-chitosan
had a positive charge of 16.4 ± 4.4mV, an average size of 320 ± 221
nm and PDI of 0.220 ± 0.012 and was considered as polydisperse.29
SeNP-chitosan size values with the ZetaSizer measurement
were higher than the supplier’s specification of 50nm average size
however TEM images confirmed those specifications (Figure 1, A
and B)
To demonstrate that SKOV3 and OVCAR3 cells were
responding to Se treatments, and therefore confirming that Se
had been effectively taken up by cells, GPX1 mRNA levels weremeasured.30 GPX mRNA levels increased 2-2.5-fold following
Se treatment in both cell types (Figure 1, C).
Ovarian cancer cell line dependent SeNP cytotoxicity
SKOV-3 and OVCAR-3 cell monolayers were treated with
increasing concentrations of SeNP-BSA, SeNP-chitosan or sodium
selenite (0 – 80 μg/mL) over 48 h and cell viability measured. For
SKOV-3 (Figure 2) cells selenite treatment had a greater cytotoxic
than SeNP-BSA and SeNP-chitosan. The IC20 for selenitewas 3 μg/
mL at 48 h (Figure 2), whereas the IC20 for SeNP-BSA and SeNP-
chitosanwere 6 μg/mL and 13 μg/mL respectively (Pb 0.05). Above
5μg/mL of selenite, SKOV-3 cell viability was significantly reduced
compared to untreated control after 48 h (P b 0.05). Whereas for
SeNP-BSA and SeNP-chitosan the concentration required to cause a
significant reduction in cell viability was 10 μg/mL and 20 μg/mL
respectively (P b 0.05).
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of nanoparticles than selenite (Figure 2), the IC20 at 48 h was
not significantly different between SeNP-BSA and SeNP-
chitosan treatment at 20 μg/mL and 18 μg/mL respectively
(P N 0.05), whereas the IC20 for selenite was 40 μg/mL (Figure
2, P b 0.05).
IC50 values confirmed SKOV-3 cells were more sensitive
than OVCAR-3 to both selenite and SeNP-BSA treatments (8 vs
56 μg/mL and 19 vs 42 μg/mL respectively, Pb 0.05), whereas
the IC50 for SeNP-chitosan the same (40 μg/mL) for both
SKOV-3 and OVCAR-3 (Figure 2, B and C). It appears that
selenite has a greater cytotoxic effect on SKOV-3 cells than
SeNPs, whereas the opposite was observed for OVCAR-3 cells,
which are more sensitive to SeNPs than selenite. The
concentrations of SeNPs required to decrease cell viability are
all significantly higher in OVCAR-3 than SKOV-3 suggesting
that the two cell types are responding differently to Se treatment
despite the GPX stimulation being similar.
Epithelial–mesenchymal transition (EMT) is a cellular
mechanism linked to differentiation during cancer progression,31
and includes alterations in E- and N-cadherin and vimentin
expression, and increased cell migration.32 Efforts to reverseFigure 7. Effect of SeNP on SKOV-3 and OVCAR -3 cell stiffness and nano-
monitor changes in cell elasticity following 48 h of treatment. Using Hertz mechan
of the force curve. The 0 point in the x-axis indicates when the cantilever tip m
frequency curve for control and treated cells at 48 h. Highly significant alterations
data reported that were applying the same force results in treated OVCAR-3 (B) ce
after treatment. Statistical significance was determined using the Mann-Whitney te
b 0.001.these transitions are an important consideration in treating
aggressive cancers. The effect of Se on cell motility was
assessed using a scratch assay, treating cells with IC20 levels of
selenite and SeNPs for 48 h. Motility rates were decreased by
25% following SeNP-BSA treatment, 17% after SeNP-chitosan
treatment and 19% with selenite (P b 0.05, Figure 3, A),
suggesting that whilst selenite was move cytotoxic the three
treatments has a similar extent in reducing cell motility. Scratch
assays were not possible with OVCAR-3 cells as these cells do
not survive when depleted with FBS. In SKOV-3 cells
assessment of EMT markers revealed that selenite and SeNPs
had no effect with E-cadherin expression remaining at very low
levels, and N-cadherin and vimentin remaining highly
expressed consistent with an unaltered mesenchymal pheno-
type. (Figure 3, B and C. In OVCAR-3 cells the E-cadherin:N-
cadherin was the opposite to that observed in SKOV-3 cells
suggestive of a more epithelial phenotype (Figure 3, B and D),
however neither marker responded to selenium treatments. In
contrast, vimentin levels significantly (P b 0.05) decreased
following treatment with SeNPs, an effect that has previously
been correlated with a decrease in cancer cell mechanical
integrity.18indentation. AFM probe with a colloidal tip was used as a nano-indentor to
ics, elasticity was calculated from the observed changes in the contact regime
akes contact with the cell surface. Total cell elasticity values are drawn in
in median values were detected between control and treated cells. Indentation
lls deforming more than control cells. SKOV-3 (A) cells seem to deform less
st with the following used symbols NS=P N 0.05, *P b 0.05 **P b 0.01, ***P
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Previously ovarian cancer cell biomechanics have been
shown to differ depending on the invasive potential of cells,16
and perturbations in gene expression patterns linked to enhanced
cellular movement, migration, and invasion.17 Given the
decreases in motility rates described above we reasoned that
this may be linked to altered biomechanical properties following
SeNP exposure. Using high-resolution tapping mode AFM we
initially resolved gross cellular morphology and nanoscale
surface topography.
SKOV-3 had an elongated, mesenchymal like, morphology
and a smooth membrane ultrastructure that remained unaltered
following treatment (Figure 4, all panels). No significant change
in cell height was observed between untreated cells (2.4 ± 0.3
μm) and those treated with selenite (2.8 ± 0.6 μm), SeNP-BSA
(2.7 ± 0.3 μm) or SeNP-chitosan (2.3 ± 0.8 μm).
OVCAR-3 cells had a spherical, epithelial like morphology
that remained unaltered following SeNP treatment (Figure 5, all
panels) consistent with the observed N-cadherin and E-cadherin
expression ratios. No significant changes in the height of
OVCAR-3 were observed between untreated (5.2 ± 0.6 μm) and
selenite (4.8 ± 0.4 μm), SeNP-BSA (5.1 ± 0.5 μm) or SeNP-
chitosan (4.0 ± 0.5 μm) treated cells (P N 0.05; Figure 5). An
increase in intra-cellular vesicles was apparent in cells with all Se
treatments in bright filed images.
Membrane topography is sensitive to changes of both
physical or chemical factors, and NP exposure has been shown
to modulate cell membranes.33 To investigate any SeNP effects
on membrane roughness, 1μm2 areas of the cell surface selected
at random from a 25 μm2 image area and analyzed for roughness.
Surface roughness increased in SKOV-3 cell treated with SeNP-
BSA (37.31 ± 1.58 nm) and SeNP-chitosan (42.89 ± 2.37 nm),
compared to untreated cells (33.08 ± 1.56 nm), whereas no
change was detected following selenite treatment (26.41 ± 1.15
nm) (P N 0.05, Figure 6). For OVCAR-3 cells the surface
roughness of SeNP treated was significantly decreased from
39.39 ± 2.48 nm in untreated controls to 28.41 ± 1.82 nm with
selenite, 27.92 ± 1.75 nm with SeNP-BSA, and 30.05 ± 1.11 nm
with SeNP-chitosan treatment (P b 0.05). There was no
significant difference in OVCAR-3 surface roughness was
observed between selenite and SeNP treatments (P N 0.05,
Figure 6).
The mechanical properties of cells change during cancer
progression, with metastatic cells becoming more elastic17
after initial transformation to enable basement membrane
penetration.34–36 To investigate whether Se treatment resulted
in any changes in cell elasticity, both SKOV-3 and OVCAR-3
cells were characterized using AFM based nanoindentation, with
a colloidal probe (Figure 7).
A significant increase in cell stiffness was observed for
SKOV-3 cells following treatment with either SeNP-BSA (3.9 ±
0.2 kPa) or SeNP-chitosan (3.4 ± 0.1 kPa) compared to control
(2.8 ± 0.1 kPa; P b 0.05), whereas no alterations were detectable
following selenite treatment (2.8 ± 0.2 kPa; P N 0.05).
Indentation analysis revealed a significant decrease for SeNP
treated SKOV-3 cells (Figure 7, A) with 600 ± 20 nm (P b 0.001)
for SeNP-BSA and 668 ± 30 nm (P b 0.05) for SeNP-chitosan incomparison with control (756 ± 30 nm) and selenite treated cells
(780 ± 31 nm). In OVCAR-3 cells the Young’s modulus was
decreased following SeNP-BSA (1.5 ± 0.1kPa), SeNP-chitosan
(1.9 ± 0.1kPa) or selenite (1.5 ± 0.1kPa) treatment compared to
the untreated control (2.5 ± 0.1kPa; P b 0.001), which together
with significantly increase in cell indentation (Figure 7, B)
following each treatment (selenite 1,141 ± 25 nm, SeNP-BSA
1,157 ± 29 nm, SeNP-chitosan 1,021 ± 34 nm) demonstrated that
cell membranes had become more deformable in comparison
with control (825 ± 28 nm, P b 0.001). Example typical force
curves have been collected and are shown in Supplementary
Figure 3.
Cellular adhesion to the AFM probe was also analyzed, with
no significant alterations in SKOV-3 or OVCAR-3 cells
respectively, as shown in Supplementary Figure 4.Discussion
Despite the anticancer properties associated with selenium, its
use as a cancer therapy has not yet been realized due to systemic
toxicity when administered in an aqueous form. Here we
demonstrated that, like selenite, SeNPs are effective at inducing a
cytotoxic effect on two different serous ovarian cancer derived
cell lines and observed distinct responses for each cell type. Both
selenite and SeNPs were cytotoxic to SKOV-3 cells, with
selenite having a 2.5- and 5- fold lower IC50 than SeNP-BSA
and SeNP-chitosan respectively. However, given that aqueous
selenium is significantly more toxic when administered system-
ically in murine models,5 ,27,28 the use of SeNP-BSA is likely to
provide an opportunity to deliver cytotoxic doses of Se in vivo.
In addition, tumor specific delivery could occur through the
enhanced permeability and retention effect,37 further reducing
toxicity. For OVCAR-3 cells SeNP-BSA and SeNP-chitosan had
an approximately 2-fold greater cytotoxic effect than selenite.
Given the above considerations, and that the IC50 for SeNPs in
OVCAR-3 cells was almost five times greater than for SKOV-3
cells, both types of SeNP are likely to be the only safe and
tolerable route for Se administration to target cancer cell growth
in vivo.
Changes in cell mobility in SKOV-3 led us to investigate cell
membrane dynamics in response to selenium treatment as we and
others have previously observed differences in ovarian cancer
cell biomechanics which were dependent on the invasive
potential of cells,16 and associated with genes involved in
enhanced cellular movement, migration, and invasion.17 De-
tailed AFM analysis revealed that SKOV-3 cells become less
elastic following SeNPs treatment but remained unchanged when
treated with selenite. This suggests that SeNPs are triggering a
mechanism that results in a lower metastatic potential, and in
agreement with the reduced migratory capacity of these cells
following treatment.20 ,22 In contrast, AFM analysis revealed that
OVCAR-3 cells became more elastic following treatment with
the higher IC20 concentrations of SeNP and selenite required to
induce a cytotoxic effect with these cells. These results highlight
specific differences in membrane architecture between SKOV-3
and OVCAR-3 and indicate that SeNP treatment can cause
differential cell type specific cytoskeletal effects.
10 B. Toubhans et al / Nanomedicine: Nanotechnology, Biology, and Medicine 29 (2020) 102258Further contrasting effects were seen with surface roughness,
which increased following SeNP treatment in SKOV-3 cells,
possibly as a result of nanoparticle internalization as previous
studies have shown that BSA coated SeNPs, similar to those used
in the present study, were internalized through endocytosis or
clathrin mediated vesicles.38–40 As selenite would be expected to
be taken up by anion transporters41 this difference in surface
roughness was anticipated. Surprisingly, the surface roughness
of OVCAR-3 cells decreased following SeNPs and selenite
treatment and was accompanied by the appearance of intracel-
lular vesicles which are likely to be autophagosomes (Figure 5,
B–D).42 ,43 This suggests that, uniquely, Se forms may induce
autophagy which would act as a resistance mechanism in
OVCAR-3 cells41 and offers an explanation as to why the levels
of SeNPs required to illicit a response is higher for these cells.
This detailed nanomechanical assessment of two distinct ovarian
cancer cell types has established that changes in the mechanical
properties of ovarian cancer cells, which are likely to result from
reorganization of the actin cytoskeleton induced by selenium.
SeNPs are effective at preventing cell proliferation in high grade
serous ovarian cancer cells, apparently through different
biological pathways. High grade serous ovarian cancers
continues to present obstacles to currently available treatment
through the presentation of advanced and highly aggressive
forms of the disease, resulting in a high rate of mortality.8 The
observations made here pave the way for further investigations
into evaluating the utility of SeNPs as a pan-cancer treatment, at
least in ovarian cancer, although Se is known to be effective in
many other cancer types.
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